

KBP Rabbit pAb

KBP Rabbit pAb
Catalog # AP59358

Product Information

Application	WB
Primary Accession	Q96EK5
Reactivity	Human
Predicted	Mouse, Rat, Horse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	71814
Physical State	Liquid
Immunogen	KLH conjugated synthetic peptide derived from human KBP
Epitope Specificity	151-250/621
Isotype	IgG
Purity	affinity purified by Protein A
Buffer	0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
SUBCELLULAR LOCATION	Mitochondrion.
SIMILARITY	Belongs to the KIF1-binding protein family.
SUBUNIT	Interacts with KIF1B.
DISEASE	Defects in KIAA1279 are the cause of Goldberg-Shprintzenmegacolon syndrome (GOSHS) [MIM:609460]. GOSHS is characterized by microcephaly, mental retardation and facial dysmorphism, as well as phenotypes related to Hirschsprung disease syndrome.
Important Note	This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
Background Descriptions	Chromosome 10 contains over 800 genes and 135 million nucleotides, making up nearly 4.5% of the human genome. PTEN is an important tumor suppressor gene located on chromosome 10 and, when defective, causes a genetic predisposition to cancer development known as Cowden syndrome. The chromosome 10 encoded gene ERCC6 is important for DNA repair and is linked to Cockayne syndrome which is characterized by extreme photosensitivity and premature aging. Tetrahydrobiopterin deficiency and a number of syndromes involving defective skull and facial bone fusion are also linked to chromosome 10. As with most trisomies, trisomy 10 is rare and is deleterious. The KIAA1279 gene product has been provisionally designated KIAA1279 pending further characterization.

Additional Information

Gene ID	26128
Other Names	KIF-binding protein, KIF1-binding protein, Kinesin family binding protein {ECO:0000312 HGNC:HGNC:23419}, KIFBP (HGNC:23419)

Target/Specificity	Highly expressed in heart, brain, ovary, testis, spinal cord and all specific brain regions examined. Moderate expressed at intermediate level in all other adult tissues examined, as well as in fetal liver and brain. Not expressed in blood leukocytes.
Dilution	WB=1:500-2000
Storage	Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.


Protein Information

Name	KIFBP (HGNC:23419)
Function	Activator of KIF1B plus-end-directed microtubule motor activity (PubMed: 16225668). Required for organization of axonal microtubules, and axonal outgrowth and maintenance during peripheral and central nervous system development.
Cellular Location	Cytoplasm, cytoskeleton
Tissue Location	Highly expressed in heart, brain, ovary, testis, spinal cord and all specific brain regions examined. Moderate expressed at intermediate level in all other adult tissues examined, as well as in fetal liver and brain. Not expressed in blood leukocytes

Background

Chromosome 10 contains over 800 genes and 135 million nucleotides, making up nearly 4.5% of the human genome. PTEN is an important tumor suppressor gene located on chromosome 10 and, when defective, causes a genetic predisposition to cancer development known as Cowden syndrome. The chromosome 10 encoded gene ERCC6 is important for DNA repair and is linked to Cockayne syndrome which is characterized by extreme photosensitivity and premature aging. Tetrahydrobiopterin deficiency and a number of syndromes involving defective skull and facial bone fusion are also linked to chromosome 10. As with most trisomies, trisomy 10 is rare and is deleterious. The KIAA1279 gene product has been provisionally designated KIAA1279 pending further characterization.

Images



Sample: Raji Cell (Human) Lysate at 30 ug
 Primary: Anti-KBP (AP59358) at 1/300 dilution
 Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
 Predicted band size: 72kD
 Observed band size: 75kD

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.